MX2015002570A - Inhibidores de la beta-secretasa. - Google Patents

Inhibidores de la beta-secretasa.

Info

Publication number
MX2015002570A
MX2015002570A MX2015002570A MX2015002570A MX2015002570A MX 2015002570 A MX2015002570 A MX 2015002570A MX 2015002570 A MX2015002570 A MX 2015002570A MX 2015002570 A MX2015002570 A MX 2015002570A MX 2015002570 A MX2015002570 A MX 2015002570A
Authority
MX
Mexico
Prior art keywords
inhibitors
secretase
beta
same
disorders
Prior art date
Application number
MX2015002570A
Other languages
English (en)
Spanish (es)
Inventor
Klaus Fuchs
Jing Yuan
Zhenrong Xu
Salvacion Cacatian
Suresh B Singh
Shankar Venkatraman
Niklas Heine
Lanqi Jia
Angel Morales-Ramos
Yajun Zheng
Yuri Bukhtiyarov
Lawrence Wayne Dillard
Cornelia Dorner-Ciossek
Deepak S Lala
Yi Zhao
Ulrike Gross
Achim Sauer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49162226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015002570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2015002570A publication Critical patent/MX2015002570A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/26—Isothiocyanates having isothiocyanate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members
    • C07C2603/97—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members containing five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015002570A 2012-08-27 2013-08-26 Inhibidores de la beta-secretasa. MX2015002570A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261693512P 2012-08-27 2012-08-27
US201361788839P 2013-03-15 2013-03-15
US201361816458P 2013-04-26 2013-04-26
PCT/US2013/056566 WO2014035860A1 (en) 2012-08-27 2013-08-26 Inhibitors of beta-secretase

Publications (1)

Publication Number Publication Date
MX2015002570A true MX2015002570A (es) 2015-10-05

Family

ID=49162226

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002570A MX2015002570A (es) 2012-08-27 2013-08-26 Inhibidores de la beta-secretasa.

Country Status (23)

Country Link
US (2) US9018391B2 (enExample)
EP (1) EP2888236A1 (enExample)
JP (1) JP2015529666A (enExample)
KR (1) KR20150046270A (enExample)
CN (1) CN104662005A (enExample)
AP (1) AP2015008261A0 (enExample)
AR (1) AR092247A1 (enExample)
AU (1) AU2013309157A1 (enExample)
BR (1) BR112015004303A2 (enExample)
CA (1) CA2879884A1 (enExample)
EA (1) EA201590410A1 (enExample)
HK (1) HK1211586A1 (enExample)
IL (1) IL236963A0 (enExample)
IN (1) IN2015DN01137A (enExample)
MD (1) MD20150030A2 (enExample)
MX (1) MX2015002570A (enExample)
PE (1) PE20150707A1 (enExample)
PH (1) PH12015500420A1 (enExample)
SG (1) SG11201500506YA (enExample)
TN (1) TN2015000032A1 (enExample)
TW (1) TW201422592A (enExample)
UY (1) UY34991A (enExample)
WO (1) WO2014035860A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101908255B1 (ko) 2009-03-13 2018-10-15 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
TWI572605B (zh) 2012-04-26 2017-03-01 必治妥美雅史谷比公司 血小板聚集之抑制劑
EP2847177B1 (en) 2012-05-09 2017-10-11 Boehringer Ingelheim International GmbH Methods for making oxetan-3-ylmethanamines
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
EP2900650A1 (en) 2012-09-28 2015-08-05 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2014081558A1 (en) 2012-11-21 2014-05-30 Boehringer Ingelheim International Gmbh PROCESS FOR MAKING N-SULFINYL a-AMINO AMIDES
KR102826937B1 (ko) 2019-09-06 2025-07-01 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Axl 및 c-Met 키나아제 억제 활성을 갖는 화합물 및 이의 제조와 응용

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
WO1993005045A1 (en) 1991-08-28 1993-03-18 The Upjohn Company Spirocyclic benzopyran imidazolines
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
NZ547462A (en) 2003-12-15 2010-06-25 Schering Corp Heterocyclic aspartyl protease inhibitors
ES2321853T3 (es) 2004-06-16 2009-06-12 Wyeth Difenilimidazopiridina e -imidazol aminas como inhibidores de b-secretasa".
ES2332659T3 (es) 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
JP2008515989A (ja) 2004-10-13 2008-05-15 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのβ−セクレターゼ阻害薬として有用なスピロピペリジン化合物
KR20080025079A (ko) 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
AU2006266167A1 (en) 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
JP4870162B2 (ja) 2005-07-29 2012-02-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 蒸気アイロンからの蒸気の噴出を生成する方法
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
WO2007038271A1 (en) 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
DE102005057688A1 (de) 2005-12-01 2007-06-14 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums
JP2009520027A (ja) 2005-12-19 2009-05-21 ワイス ２−アミノ−５−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用
EP1974278A4 (en) 2005-12-20 2012-01-04 Fieldbus Foundation SYSTEM AND METHOD FOR IMPLEMENTING INSTRUMENTED SAFETY SYSTEMS
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2644600B1 (en) 2006-06-12 2017-01-11 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
DK2042480T3 (da) 2006-07-18 2013-05-27 Astellas Pharma Inc Aminoindan-derivat eller salt deraf
JP2010502705A (ja) 2006-09-07 2010-01-28 メルク エンド カムパニー インコーポレーテッド アルツハイマー病の治療用としてのスピロピペリジンベータセクレターゼ阻害剤
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
CL2008000784A1 (es) 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
PE20090617A1 (es) 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
UY31083A1 (es) 2007-05-15 2009-01-05 Astrazeneca Ab Derivados de sulfoximinas para la inhibicion de b-secretasa
EP2077637B1 (en) 2007-12-12 2020-03-11 Alcatel Lucent System and method for protecting payload information in radio transmission
ES2398017T3 (es) 2008-02-18 2013-03-13 F. Hoffmann-La Roche Ag Derivados de 4,5-dihidro-oxazol-2-il-amina
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
KR20110048491A (ko) 2008-07-28 2011-05-11 에자이 알앤드디 매니지먼트 가부시키가이샤 스피로아미노디하이드로티아진 유도체들
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
KR101908255B1 (ko) 2009-03-13 2018-10-15 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
TWI557112B (zh) * 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑

Also Published As

Publication number Publication date
AU2013309157A1 (en) 2015-02-19
KR20150046270A (ko) 2015-04-29
TN2015000032A1 (en) 2016-06-29
MD20150030A2 (ro) 2015-08-31
BR112015004303A2 (pt) 2017-08-08
US20140057927A1 (en) 2014-02-27
EP2888236A1 (en) 2015-07-01
PH12015500420B1 (en) 2015-04-20
PE20150707A1 (es) 2015-06-14
IL236963A0 (en) 2015-03-31
CN104662005A (zh) 2015-05-27
WO2014035860A1 (en) 2014-03-06
HK1211586A1 (zh) 2016-05-27
AR092247A1 (es) 2015-04-08
AP2015008261A0 (en) 2015-02-28
US9018391B2 (en) 2015-04-28
PH12015500420A1 (en) 2015-04-20
CA2879884A1 (en) 2014-03-06
IN2015DN01137A (enExample) 2015-06-26
EA201590410A1 (ru) 2015-06-30
UY34991A (es) 2014-03-31
TW201422592A (zh) 2014-06-16
WO2014035860A8 (en) 2015-01-15
JP2015529666A (ja) 2015-10-08
SG11201500506YA (en) 2015-04-29
US20150239849A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
PH12014501963A1 (en) Inhibitors of beta-secretase
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
PH12015500420A1 (en) Inhibitors of beta-secretase
MX2013005549A (es) Aminas heterociclicas y sus usos.
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MD20150023A2 (ro) Piridinone biciclice noi
GB2533454A (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017016055A (es) Moduladores alostericos positivos del receptor muscarinico m2.
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
GB201115977D0 (en) Neurodevelopmental disorders
WO2014052398A8 (en) Inhibitors of beta-secretase
MA37955A1 (fr) Inhibiteurs de bêta-secrétase